Gilead Sciences Inc. stock underperforms Friday when compared to competitors
Shares of Gilead Sciences Inc. sank 0.06% to $66.94 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500... · 1d ago
AstraZeneca PLC ADR rises Friday, outperforms market
The AstraZeneca PLC ADR advanced 1.33% to $53.25 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ... · 1d ago
Diverticular Disease Therapeutics Market to See Huge Growth by 2028 | Companies Shire Plc., Cook Group Incorporated, Allergen Plc., Salix Pharmaceuticals Inc. novoGI, Inc.
Markitwired · 1d ago
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes · 1d ago
US Thalassemia Treatment Market Size, Share, Global Industry Analysis, Revenue, Trend And Top Growing Companies to 2027
Jan 22, 2021 (Heraldkeepers) -- Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy...
Heraldkeepers · 1d ago
Wet Macular Degeneration Market Outlook 2026: Top Companies, Trends and Growth Factors Details for Business Development
Jan 22, 2021 (The Expresswire) -- The global “Wet Macular Degeneration Market” Report deliver comprehensive analysis of the market structure along with...
The Express Wire · 2d ago
Infectious Disease Drugs Market Size, Demand-sales, Suppliers By Key Applications 2020 Detailed Analysis and Growth Aspects on Manufacturing Landscapes
Comserve · 2d ago
Anti-infective Drugs Market Growth Analysis By Revenue, Size, Share, Scenario on Latest Trends & Types, Applications 2020 to 2025 Forecast
Japan, Japan, Fri, 22 Jan 2021 01:32:47 / Comserve Inc. / -- The report offers overview of leading companies encompassing their successful marketing...
Comserve · 2d ago
Cystic Fibrosis Drugs Market Share, Global Leading Players 2021, Business Overview, Size Estimation, Revenue, Key Drivers by Manufacturers, Upcoming Trends to Forecast 2026
The Express Wire · 2d ago
Pfizer, GSK-Backed ViiV First To Get FDA Approval For HIV Shots: What You Need To Know
In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration.
Benzinga · 2d ago
Alexion Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Alexion Pharmaceuticals Inc. inched 0.08% higher to $157.86 Thursday, on what proved to be an all-around mixed trading session for the stock... · 2d ago
Gilead Sciences Inc. stock falls Thursday, underperforms market
Shares of Gilead Sciences Inc. slid 1.49% to $66.98 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500... · 2d ago
AstraZeneca PLC ADR outperforms market on strong trading day · 2d ago
AbbVie, Roche, Glaxo Are Experts at Product Launches
GuruFocus News · 2d ago
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
Business Wire · 2d ago
Here are the 10 executive orders Biden signed to combat the Covid pandemic
As the new administration implements the federal initiatives, it will also emphasize the safe reopening of schools and businesses, the plan says. · 2d ago
Worldwide HIV Drugs Industry to 2027 - Impact Analysis of COVID-19
DUBLIN, Jan. 21, 2021 /PRNewswire via COMTEX/ -- DUBLIN, Jan. 21, 2021 /PRNewswire/ -- The "Global HIV Drugs Market By Medication Class, Non-nucleoside...
PR Newswire - PRF · 2d ago
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead? · 2d ago
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
Zacks · 2d ago
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar · 2d ago
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.